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ABSTRACT. The purpose of this study was to assess the clinical effect of nebulized formoterol (FM), ipratropium 
bromide (IB) and furosemide (FS) combined with fluticasone propionate (FP) on lung function in premature calves 
with Respiratory Distress Syndrome (RDS). Thirty-six premature calves with RDS were randomly assigned to six 
different treatment groups (D1 to D6). All groups received the standard treatment, including oxygen and support treat-
ment. Calves in D1 received only the standard treatment. The following combinations of nebulized drugs were used for 
the other groups: D2: FP, D3: FP+FM; D4: FP+IB; D5: FP+FS and D6: FP+IB+FM+FS. The treatment period (72 h) 
involved the application of FM (15 µg totally/12 h), IB (2 µg/kg/12 h), FS (1 mg/kg/12 h) and FP (15 µg/kg/12 h) for 
five minutes. A significant increase over time in blood pH, partial pressure of oxygen (PaO2), oxygen saturation (SatO2) 
and a decrease in partial pressure of carbon dioxide (PaCO2) and lactate were detected in all groups that received nebu-
lized treatment; while in the D1, a significant change was observed only for PaCO2. Calves in D6 had the highest PaO2 
and lowest PaCO2 values amongst all groups at the end of treatment. No statistical difference was observed between the 
Nebulization Groups (NG). Nebulized FM, IB and FS with FP combination in premature calves with RDS, in addition 
to the standard treatment showed a significant curative effect on lung function.
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INTRODUCTION
Premature calves often suffer from life-threatening disorders due to incomplete development of or-
gans, such as lungs, (Bleul, 2009) resulting in a de-
creased gas exchange capacity due to decreased lung 
volume and capillary surface area. An insufficient ex-
change of gas results in hypoxemia and long-lasting 
oxygen requirements (Ok and Birdane, 2000; Aydoğ-
du et al., 2016). In premature infants, surfactant de-
ficiency and inflammation-associated fibrosis have 
been reported to play an important role in increasing 
the respiratory distress syndrome (RDS) risk (Murch 
et al., 1996).
The availability of nebulized drugs alleviates 
the clinical signs of RDS and improves pulmonary 
function (Genicot et al., 1994; Yildiz and Ok, 2017). 
Fluticasone propionate (FP) is one of the most com-
monly used inhaled steroids to reduce inflammation 
in pulmonary disorders and for treatment of asthma 
symptoms. It is also extensively used for treating re-
spiratory problems in horses (Robinson et al., 2009) 
and in premature calves with RDS (Yildiz and Ok, 
2017). Diuretics, such as furosemide (FS), decrease 
interstitial oedema and pulmonary vascular resistance 
and facilitate gas exchange; thereby reduce oxygen 
consumption (Bancalari et al., 2005). Inhaled FS has 
been considered to improve lung function in prema-
ture calves with RDS (Yildiz and Ok, 2017). Beta-2 
adrenergic or anticholinergic aerosols are useful in 
treating bronchial constriction in preterm infants and 
they have been known to relieve from acute respira-
tory distress (Jarjour et al., 2006). Formoterol (FM) 
and ipratropium bromide (IB) are long-acting β-2 ad-
renergic agonists, which exert their action by relaxing 
the smooth muscles of the respiratory tract. The onset 
of action of FM is rapid and has been shown to exert 
long-lasting bronchodilation in children with bronchi-
al asthma (Faulds and Hollingshead, 1991). Leemans 
et al., (2009) found that inhaled salbutamol and IB 
were effective in the treatment of respiratory disor-
ders in cats. 
Therefore, the hypothesis of this study was wheth-
er the administration of nebulized FP combined with 
FM, IB and FS, additionally to oxygen therapy and 
standard clinical care, significantly improves the con-
dition of premature calves with RDS, just as reported 
in human, feline and equine neonates.
MATERIALS AND METHODS
Animals: Thirty-six premature calves of different 
breeds (Holstein, n=27; Simmental, n=5 and Brown 
Swiss, n=4) diagnosed with RDS were admitted to the 
Animal Hospital of the Faculty of Veterinary Medi-
cine of Selcuk University, within 2-12 h of birth. A 
number from 1 to 6 was randomly assigned to these 
premature calves using a random number genera-
tor, as follows: D1 (n=6), D2 (n=6), D3 (n=6), D4 
(n=6), D5 (n=6) and D6 (n=6). D1 was considered 
the standart treatment group whereas D2, D3, D4, D5 
and D6 the nebulized treatment groups. Inclusion cri-
teria were the gestational age (230 to 260 days) and 
RDS following a clinical examination (Yildiz and 
Ok, 2017). RDS criteria for premature calves includ-
ed: hypoxemia (PaO2 < 60 mm Hg in arterial blood); 
hypercapnia (PaCO2 > 45 mm Hg in arterial blood); 
tachypnea (respiratory rate; RR ≥ 45 breaths/min) and 
expiration accentuated by an abdominal lift (Bleul et 
al., 2008; Yildiz and Ok, 2017). Peripheral oxygen sat-
uration (SpO2) was measured using a patient monitor 
device (Compact, Econet, Germany) and calves were 
clinically examined during the study. Calves having 
RDS as a result of other underlying diseases such as 
aspiration pneumonia or trauma were excluded from 
the study. Approval of the study was obtained from 
institutional ethics board of the Veterinary Faculty of 
Selcuk University (no: 2014/05).
Sample collection and blood analysis 
Sodium heparin-containing plastic insulin syring-
es were used for the collection of arterial blood sam-
ples anaerobically from the arteria auricularis, as 
described in a previous study (Yildiz and Ok, 2017). 
Arterial blood pH, PaO2, PaCO2, SatO2, lactate and 
base excess (BE) were analysed within 15 min at 0, 
24, 48 and 72 h using a blood gas analyser (GEM Pre-
mier 3000, Instrumentation Laboratory, Lexington). 
The 0 h represents the time just before the initiation of 
the treatment and immediately after the collection of 
blood sample the nebulized drugs were administered 
over a course of 5-20 min depending on the combina-
tion of the drugs. 
Standard treatment and oxygen therapy protocol 
for premature calves 
Standard treatment, including oxygen therapy, 
supportive treatment and clinical care, was provided 
to each calf in all groups. Supportive treatment and 
clinical care protocols are described by Yildiz and Ok 
(2017) and oxygen therapy via mask by Bleul et al. 
(2008). 
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Nebulizer treatment protocol for premature 
calves 
While calves in the D2 to D6 received nebulizer 
drugs for 5 min, calves in the control group received 
only 2.5 mL saline solution (every 12 h for 72 h) for 5 
min via a nebulizer machine (NebuTech, GmbH, Ger-
many). The nebulizer drug combinations were admin-
istered as follows: D2: FP; D3: FP + FM; D4: FP + IB; 
D5: FP + FS and D6: FP + FM + IB + FS.
Brand names of the drugs and dosages enrolled in 
the study as follows; FM (VENTOFOR, Liconsa A.S, 
Spania), 15 µg totally, BID, 3 days; IB (ATROVENt, 
Boehringer Ingelheim, Istanbul, Turkey), 2 µg / kg, 
BID, 3 days, FS (DIURIL, Vetaş, İstanbul, Turkey), 1 
mg/kg, BID, 3 days, FP (FLIXOTIDE, GlaxoSmith-
Kline, Australia), 15 µg/kg, BID, 3 days. Each drugs 
were diluted with 2.5 mL saline solution and were ad-
ministered for 5 min using a nebulizer machine (Fig 1).
Figure 1. Nebulized drug admistration to premature calves.
Statistical analysis 
Normality of data was assessed with the Kolm-
ogorov-Smirnov test. To evaluate differences in re-
sults among the groups One-way ANOVA (Duncan’s 
posthoc multiple comparison test) were used and the 
Kruskal-Wallis test was used with non-normally dis-
tributed data. The level of significance was set at P 
< 0.05. Data were analysed with a statistical softwa-
re package (IBM SPSS, version 14.01 for Windows, 
SPSS Inc, Chicago).
RESULTS
In this study, 88.8% of premature calves with RDS 
(32/36) responded well to the therapy. Out of the 32 
calved that survived, 28 belonged to the nebulized 
treatment groups (D2 to D6). Four premature calves 
with RDS died (D1, n=2; D4, n=1 and D6, n=1). 
Generally, the symptoms observed during the clini-
cal examination of premature calves were: apnea or 
tachypnea, abdominal lift, weakness, cyanosis, hypo-
thermia, wheezing and grunting sounds, lack or ab-
sence of sucking reflex, depression and increased cap-
illary refill time . Symptoms such as tachycardia due 
to bronchodilator applications and hyperglycaemia 
due to corticosteroids were not observed. There were 
no differences in gestational age and admitted time to 
clinic after birth among the experimental groups. All 
data are presented as mean and standard error of the 
mean (mean ± SEM).
Blood gas findings 
The parameters of arterial blood gas in premature 
calves with RDS are presented in Table 1.
In D2 to D6, there are marked increases in val-
ues including pH, pO2, SatO2 and decreases in pCO2 
and lactate levels. These values with their significance 
was presented separately in our group results.
Group D1: No significant differences were ob-
served in blood gas parameters during the treatment. 
The gestational age at birth was 246 ± 3.79 days and 
admitted time to clinic after birth was 7.33 ± 1.45 h 
of the group.
Group D2: Significant increases was seen in val-
ues of blood pH, BE and SatO2 at 24, 48 and 72 h 
during the treatment. Additionally, a decrease in lac-
tate and PaCO2 were obtained at 24, 48 and 72 h in 
this group (Table 1). The birth age was mean 248 ± 
3.39 day and admitted time to clinic after birth was 
mean 7.17 ± 1.19 hour of the group.
Group D3: A significant (P < 0.05) increase in the 
blood pH, BE and SatO2 values was obtained at the 
24, 48 and 72 h of the treatment. A decrease in lactate 
and PaCO2 value at 24, 48 and 72 h was also seen in 
these calves. A significant (P < 0.05) increase in PaO2 
value at 24, 48 and 72 h was found (Table 1). The 
birth age was mean 247 ± 3.93 day and admitted time 
to clinic after birth was mean 5.83 ± 1.16 hour of the 
group.
Group D4: A significant (P < 0.05) increase in 
blood pH, PaO2 and SatO2 values with a decrease in 
lactate and PaCO2 values was seen in the calves at 24, 
48, and 72 h of treatment. The birth age was mean 243 
± 2.70 day and admitted time to clinic after birth was 
mean 6.67 ± 1.26 hour of the group.
Group D5: A significant (P < 0.05) increase in 
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blood pH, BE and SatO2 values during 24, 48 and 72 
h of the treatment was seen. In addition, a decrease in 
lactate values during 48 and 72 h and PaCO2 values 
at the 72 h was found in this group. No significant 
difference was observed in PaO2 value of premature 
calves with RDS (Table 1). The birth age was mean 
244 ± 3.52 day and admitted time to clinic after birth 
was mean 6.33 ± 1.45 hour of the group.
Group D6: A significant (P < 0.05) increase in 
blood pH, BE and SatO2 values during the 24, 48 and 
72 h and while there were no significant difference 
between 0 h and 24 h, a significant increase in PaO2 
value between the 24, 48 and 72 h was seen in this 
group. A decrease in lactate value during the 48 and 
72 h and PaCO2 value during the 24, 48 and 72 h were 
seen in this group (Table 1). The birth age was mean 
246 ± 4.16 day and admitted time to clinic after birth 
was mean 5.83 ± 1.92 hour of the group.
Table 1. Arterial blood gas values in the all premature calves with RDS in the present study (Mean±SEM)
 Parameters  Groups 0. hour 24. hour 48. hour 72. hour
pH
D1 7.11±0.11 b 7.26±0.09aB 7.31±0.10a 7.38±0.12a
D2 7.29±0.04b 7.45±0.03aA 7.47±0.04a 7.47±0.02a
D3 7.31±0.02b 7.44±0.02aA 7.46±0.01a 7.48±0.01a
D4 7.24±0.08b 7.44±0.02aA 7.47±0.03a 7.47±0.01a
D5 7.09±0.1b 7.41±0.03aA 7.43±0.03a 7.48±0.02a
D6 7.30±0.04c 7.41±0.01bA 7.46±0.01ab 7.50±0.01a
PaCO2 
mmHg
D1 61.6±7.48 55.3±8.29A 53.8±6.58A 50.6±7.77
D2 54.3±5.38a 39.3±1.61bB 39.0±3.86bB 42.3±2.74b
D3 50.6±3.9a 42.1±2.23bB 39.0±1.93bB 39.8±1.62b
D4 57.3±6.98a 44.0±2.34bAB 42.2±1.83bB 42.4±2.77b
D5 58.1±7.35a 45.6±3.01abAB 46.0±3.06abAB 42.1±3.15b
D6 49.1±0.79a 41.5±1.52bB 39.0±1.95bB 37.8±0.80b
PaO2 
mmHg
D1 33.5±5.14 36.3±5.67 39.6±7.2 43.5±7.32B
D2 37.6±4.62 50.6±4.93 52.8±5.06 50.3±4.72AB
D3 36.3±1.91c 45.5±4.01b 54.5±3.06a 55.3±1.76aAB
D4 33.8±4.16b 46.8±5.9ab 45.8±7.08ab 56.6±5.26aAB
D5 38.0±5.67 39.8±6.11 43.3±5.71 48.5±5.57AB
D6 36.5±3.84c 44.0±2.91c 55.4±2.38b 60.2±3.17aA
BE
D1 -9.75±4.62B -3.30±4.33B 0.27±4.88 4.10±6.04
D2 -1.48±1.41bAB 3.40±1.47aA 4.13±1.52a 6.95±1.19a
D3 -1.2±1.22bAB 4.20±1.53aA 4.18±0.96a 6.07±1.91a
D4 5.52±2.50A 5.17±1.12A 6.52±1.84 6.70±1.98
D5 -5.4±3.92bB 3.40±1.41aA 5.18±2.21a 6.75±1.77a
D6 -3.6±2.33bAB 1.18±0.61aAB 3.88±1.44a 5.90±1.33a
SatO2 %
D1 41.3±11.7 54.0±11.8B 60.1±13.64B 69.1±12.5B
D2 61.3±10.4 83.5±6.45A 84.8±6.64A 85.0±4.63AB
D3 62.6±3.28b 83.0±5.01aA 89.1±1.62aA 90.5±0.72aA
D4 52.3±10.2b 80.1±4.77aA 78.0±8.79aAB 89.8±2.03aA
D5 38.0±13.1b 68.1±7.89aAB 75.1±5.63aAB 83.5±4.16aAB
D6 59.0±7.47b 76.0±5.54aAB 89.8±1.16aA 90.2±1.56aA
Lactate
mmol/L
D1 7.95±2.55AB 5.65±1.96AB 4.88±2.08 4.03±2.23
D2 3.67±0.47aB 1.55±0.41bC 1.30±0.31b 0.75±0.07b
D3 4.23±0.61aAB 1.47±0.10bC 1.18±0.28b 0.78±0.10b
D4 5.72±0.89aAB 2.82±0.46bBC 1.44±0.19ab 0.92±0.15b
D5 8.9±2.27aA 4.08±1.19abABC 3.48±2.03b 2.58±1.16b
D6 7.95±1.07aAB 6.38±1.32aA 2.94±0.79b 2.62±1.05b
Different letters in the same row (a, b), in the same column (A, B) are statistically significant (P < 0,05), pH: 
concentration of hydrogen ions, PaCO2: partial pressure of arterial carbon dioxide, PaO2 partial pressure of arterial 
oxygen, SatO2%: oxygen saturation, SEM: Standart error of mean.
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pH: The pH value was significantly (P < 0.05) in-
creased in all groups at 24 h. However, on compar-
ing with D1, it was found that the nebulizer groups 
showed a statistically higher (P < 0.05) pH value at 
the 24 h. Yet, no statistical difference was observed 
between the nebulizer groups (Table 1).
PaCO2: The values of PaCO2 showed a statistical 
decrease (P < 0.05) at 24 and 48 h in D3, D4 and D6 
groups as compared to D1 group. D6 group showed 
the lowest mean value of PaCO2 amongst all groups 
at the end of the treatment. However, no statistical dif-
ference was observed between the nebulizer groups 
(Table 1).
PaO2: On comparing D1 with nebulizer treatment 
groups, it was seen that all the nebulizer treatment 
groups except D6 did not show any statistical differ-
ences at the 72 h. D6 showed the highest value (P < 
0.05) of PaO2 amongst all groups at 72 h (Table 1). 
Yet, no statistical difference was seen amongst the 
nebulizer groups (Table 1).
BE: On comparing D1 group with nebulizer treat-
ment groups, D2, D3, D4 and D5 showed statistical 
differences (P < 0.05) at the 24 h. But no statistical 
difference was determined amongst the nebulizer 
groups (Table 1).
SatO2: On comparing D1 group with nebulizer 
treatment groups, statistical differences (P < 0.05) 
were seen in D2, D3, D4 at the 24 h, in D2, D3, D6 at 
the 48 h, and in D3, D4, D6 at the 72 h. However, no 
statistical difference was observed amongst the nebu-
lizer groups (Table 1).
Lactate: On comparing D1 group with nebulizer 
treatment groups, a statistically significant difference 
was observed in lactate value at 24 h in D2, D3 and 
D6. Though there was no statistical difference be-
tween the groups at the end of the treatment, the high-
est mean value of lactate was found in D1 (Table 1).
Amongst the calves that did not survive, high 
values of lactate (> 8.5 mmol/L) and PaCO2 (> 75 
mmHg) and low levels of PaO2 (< 40 mmHg) and 
SatO2 (< 52%) were observed before death. The clin-
ical symptoms of the non-survive premature calves 
were continuous abdominal respiration, high RR (> 
70/min), absence of sucking reflex, abdominal disten-
sion related with feeding and low body temperature 
(34-36.5 °C). Parameters used for monitoring and 
clinical observations, including rectal temperature re-
spiratory rate and peripheral oxygen saturation (SpO2) 
are presented in Table 2.
Table 2. Monitoring and clinical parameters of the premature calves with RDS in the present study (Mean±SEM)
Paramaters Groups 0. hour 24. hour 48. hour 72. hour
Temperature (°C) 
D1 35.5±0.75bAB 38.3±0.41aAB 38.3±0.34aAB 38.4±0.20a
D2 36.1±1.01bAB 38.3±0.14aAB 38.6±0.35aAB 38.7±0.23a
D3 37.7±0.50A 38.7±0.21A 38.5±0.16AB 38.3±0.25
D4 36.0±1.32b 38.0±0.30abAB 38.8±0.20aA 38.7±0.30a
D5 34.6±1.03bB 37.6±0.42aAB 38.1±0.14aAB 38.6±0.29a
D6 36.2±0.78bAB 37.4±0.62abB 38.0±0.15aB 38.5±0.15a
Respiratory rate 
(minute) 
D1 51.3±9.22 64.6±13.8 58.3±13.6 56.0±14.9
D2 47.5±10.3 58.8±12.3 65.6±15.3 35.0±5.26
D3 49.6±6.4 45.2±9.33 44.8±4.59 37.2±2.58
D4 54.3±7.51 52.3±7.47 44.4±7.55 37.5±5.66
D5 49.8±6.73 58.0±13.2 50.3±7.23 35.0±5.99
D6 68.0±8.10a 49.5±7.51b 44.0±7.23b 36.0±4.47b
SpO2 (%)
D1 74.0±6.87b 85.0±5.97ab 89.5±4.97abAB 87.5±1.76a
D2 79.4±8.40 91.6±2.48 95.3±1.76A 95.5±1.44
D3 83.1±3.15b 92.6±1.15a 94.8±0.83aA 93.5±0.99a
D4 75.1±4.19b 85.3±2.85a 88.8±0.86aAB 90.6±3.11a
D5 70.5±4.92b 85.8±4.16a 84.3±3.49aB 90.3±3.12a
D6 83.5±3.38 87.5±1.54 88.8±1.59AB 90.8±3.26
Different letters in the same row (a, b), in the same column (A, B) are statistically significant (P < 0,05), SpO2 (%): 
Peripheral oxygen saturation, SEM: Standart error of mean.
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DISCUSSION
Although numerous medical treatment strategies 
in human medicine, such as antenatal steroids, sur-
factant replacement, nitric oxide administration, and 
mechanic ventilation strategies (Sahni and Phelps, 
2011), there has been no shown economically useful 
intervention to treat the RDS of premature calves, ex-
cept for a study (Yildiz and Ok, 2017) to date. 
A reliable method for the evaluation of pulmonary 
function (Bleul et al., 2007) is to determine arterial 
blood pCO2 and pO2. PaO2 of less than 60 mmHg is 
considered to be indicative of RDS in infants (Verder 
et al., 1999). In healthy calves after birth, PaO2 lev-
els were showed to vary between 47 to 58 mmHg. In 
the calves with RDS one after birth, PaO2 levels were 
found to change between 29 ± 12 and 38 ± 8.8 (Bleul, 
2009). Yildiz and Ok (2017) reported that the mean 
value of PaO2 levels in the premature calves with RDS 
at admitted to the clinic was found to be between 28 ± 
3.5 and 36 ± 5.4 mmHg. In present study, the value of 
PaO2 at 0 h was found to be between 33 ± 5.1 and 38 ± 
5.6 mmHg (Table 1) and these animals posed difficul-
ty in respiration (Table 2), which can be considered 
pathognomonic for all treatment groups. The mean 
value of PaO2 was observed to be above 50 mmHg at 
the 72 h in all nebulizer groups, except D5. In addition, 
the mean respiratory rate reverted back to the normal 
level (< 45 RR/min) in the nebulizer treatment groups 
(Table 2). The mean value of PaO2 in D6 increased to 
mean 60 ± 3.1 mmHg, and that of RR/min decreased 
to 36 ± 4.4 at the 72 h (Table 1-2). However, only the 
mean value of PaO2 in D6 reached above the specified 
critical value (60 mmHg) (Bleul, 2009). This is indi-
cating that nebulized treatment has a positive effect in 
pulmonary function. The level of PaO2 in D1 at the 72 
h was found to be 43.5 ± 7.32 mmHg (Table 1), while 
the mean respiratory rate continued to be 56 RR/min 
(Table 2). The level of PaO2 below 45 mmHg is likely 
to be pathognomonic for RDS with significant clini-
cal signs such as high respiratory rate (> 45 RR/min) 
(Bleul, 2009; Yildiz and Ok, 2017). Oxygen therapy 
is recommended for use in any newborn where SatO2 
is less than 90% or PaO2 is less than 60 mmHg. The 
low levels of arterial SatO2 (50.6 ± 7.7) in D1 indicate 
that the treatment without nebulized drugs may be in-
sufficient to raise the level of SatO2 up to the recom-
mended values (Palmer, 2005; Yildiz and Ok, 2017). 
On the other hand, a combination of inhaler FP along 
with FM, IB and FS in addition to the standard treat-
ment increases the value of SatO2 adequately to the 
recommended levels (Palmer, 2005; Yildiz and Ok, 
2017) in premature calves with RDS. Inefficient vital 
capacity of premature calves impairs the elimination 
of carbon dioxide from lungs, increasing its level in 
blood resulting in respiratory acidosis (Bleul et al., 
2007) and the increase in the level of PaCO2 above 45 
mmHg indicates to RDS (Bleul et al., 2008). Yildiz 
and Ok (2017) reported that the levels of PaCO2 (50 
to 74 mmHg) in premature calves with RDS signifi-
cantly decreased by the inhaler therapy. In our study, 
the levels of PaCO2 were determined that higher than 
49 mmHg in all premature groups at 0 h (Table 1). 
The PaCO2 values decreased in all groups during the 
treatment period (Table 1). The results of this study 
are consistent with the previous studies (Bleul et al., 
2007; Yildiz and Ok, 2017). The studies (Bleul, 2009; 
Güzelbekteş et al., 2012; Yildiz and Ok, 2017) sug-
gested that blood pCO2 and lactate levels are import-
ant biomarkers for the detection of tissue hypoxia in 
premature calves. The concentration of plasma lactate 
greater than 4 mmol/L is a predictor for death within 
24 h in cattle with pneumonia (Coghe et al., 2000). In 
a study with premature calves (Yildiz and Ok, 2017) 
has been reported that the mean lactate levels before 
the treatment were between 3.9 and 8.4 mmol/L and 
they also reported that in premature calves which 
were treated with nebulized drug combination with 
oxygen decreased the lactate to the normal level (< 2 
mmol/L) however, in the premature calves that were 
treated only with oxygen therapy, the mean lactate 
level did not fall below the critical level (4 mmol/L). 
In the present study, mean lactate concentration at 0 h 
ranged between 3.67 and 7.95 mmol/L for all groups 
(Table 1). A significant (P < 0.05) decrease in the 
blood lactate levels below  the critical value was seen 
at the 72 h in the nebulizer treatment groups (Table 
1). However, the lactate levels of premature calves 
who did not receive nebulized treatment (D1 group) 
showed no significant decrease during the course of 
the treatment and did not fall below the critical level 
even at the 72 h (Table 1). Yildiz and Ok (2017) re-
ported that high lactate (> 10 mmol/l) and PaCO2 (> 
74 mmHg) levels may be an indicator for high risk 
of death in premature calves with RDS. And also, in 
premature calves with RDS, Yildiz et al. (2017) re-
ported that the cut-off values for lactate and pCO2 
were 7.5 mmol/L and 63.5 mmHg, respectively and 
positive correlation was found between mortality and 
increasing lactate and pCO2 levels. In this study, pre-
mature calves which have lactate level higher than 
8.5 mmol/L were non-survived like previous studies 
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(Yildiz et al., 2017; Yildiz and Ok, 2017). Premature 
calves had high CO2 and low base excess levels along 
with decreased pH at admission to hospital (Yildiz et 
al., 2017). Yildiz and Ok (2017) found that the pH 
values of arterial blood in premature calves that re-
ceived nebulized treatment were within the normal 
range (7.35-7.45) at the 72 h of the study except in 
those premature calves who did not receive nebulized 
treatment (pH < 7.35). In D1, the pH value remained 
below normal, possibly due to the continued CO2 re-
tention in blood (Bleul et al., 2007), since the mean 
value of PaCO2 was found to be more than 50 mmHg 
at the 24 and 48 h of the treatment (Table 1).
The findings of this study show that nebulized 
therapy is beneficial for pulmonary functions in pre-
mature calves. These effects were most likely associ-
ated with nebulized FP combination with FM, IB, and 
FS. FP is known to reduce the release of inflammatory 
mediators in the lungs resulting from anoxic condi-
tions (Robinson et al., 2009). FM and IB, the inhaled 
bronchodilators, have been reported to be effective 
in improving lung function and decreasing the respi-
ratory symptoms (Duvivier et al., 1999; Chhabra et 
al., 2006) and also preventing neutrophilic infiltration 
and pulmonary oedema (Zhang et al., 2010). Inhaler 
diuretics like furosemide improve pulmonary compli-
ance (Broadstone et al., 1991).
CONCLUSIONS
In conclusion, despite numerous medical advanc-
es, no single intervention will prevent or treat the 
RDS of premature calves. The use of nebulized drugs 
provides short-term improvement in lung mechanics, 
still these results do not support to use of these drugs 
instead of surfactant. But the drug combinations can 
be used in veterinary practice due to their ease of ap-
plicability and low cost for to reduce the serious dam-
age due to the RDS in the first few days. The thera-
peutic effect of nebulized FP combination along with 
FM, IB, and FS on pulmonary function is a promising 
treatment for premature calves with RDS.
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